Risks

High net debt to EBITDA and zero interest coverage increase refinancing sensitivity, leaving INGN more exposed than larger medtech peers with stronger earnings buffers.

A 54-day cash conversion cycle ties up working capital, which can constrain flexibility versus peers with faster collections and inventory turns in slower demand periods.

Elevated days sales outstanding and inventory outstanding raise the risk of channel or procedure timing volatility, pressuring cash generation more than leaner competitors.

Modest current and quick ratios provide near-term liquidity support, but they do not fully offset leverage-driven vulnerability relative to better-capitalized peers.

Opportunities

Strong current and quick ratios support operating resilience, giving INGN more short-term flexibility than highly levered peers if reimbursement or demand softens.

Low debt-to-equity relative to many medtech peers can preserve strategic optionality, helping INGN fund growth initiatives without immediate balance-sheet stress.

If procedure volumes improve, the company can convert its working-capital base into cash more effectively than peers with weaker liquidity, supporting recovery potential.

The absence of near-term interest burden in coverage metrics can amplify upside from margin improvement versus peers already constrained by heavier financing costs.

Overall Score

INGN’s forward positioning is constrained by leverage and working-capital drag versus peers, while liquidity and balance-sheet flexibility provide some upside if demand and cash conversion improve.